DUTCH CARDIOTOX REGISTRY:

Conditions: Heart failure
10019280

Registration Number: NL-OMON51393

Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 1400

Inclusion Criteria

To be eligible participating in this study, patients must meet all the
following criteria:
• Patients who visit a specialized cardio-oncology unit.
• Age >=18 years.
• Written informed consent.

Exclusion Criteria

To improve the precision of cardiotoxicity definitions, patients with
pre-existing symptomatic heart failure or left ventricular ejection fraction
(LVEF) <40%, patients in whom baseline biomarkers and/or baseline
echocardiographic data were not complete and those who died within 3 months
will be excluded.
Conditions that affect a patient*s ability to provide written informed consent,
such as psychiatric or mental disorders, language barriers or other factors.

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary Objective:<br /><br>Register the incidence of cardiovascular toxicity of anticancer treatment.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary Objectives:<br /><br>Identification of risk factors for cardiotoxicity.<br /><br>Improvement in the early detection of cardiotoxicity by imaging modalities such<br /><br>as echocardiography (or even cardiac CT or cardiac MRI when available).<br /><br>Describe long-term outcomes of patients that received anticancer regimens.<br /><br>Describe therapeutic approaches currently used in the treatment of cancer<br /><br>therapy-related cardiac dysfunction.</p><br>